Commentary: Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis

Ina Zhang; Jeroen P Jansen; Benjamin J Yungher; Adrian Kielhorn; Karen S Yee

doi:10.3389/fimmu.2024.1403802

Commentary: Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis

Front Immunol. 2024 May 17:15:1403802. doi: 10.3389/fimmu.2024.1403802. eCollection 2024.

Authors

Ina Zhang¹, Jeroen P Jansen¹, Benjamin J Yungher², Adrian Kielhorn², Karen S Yee²

Affiliations

¹ Evidence Synthesis and Decision Modeling, PRECISIONheor, Oakland, CA, United States.
² Alexion, AstraZeneca Rare Disease, Boston, MA, United States.

No abstract available

Keywords: B-cell targeting therapy; FcRn inhibitor; complement inhibitor; generalized myasthenia gravis; monoclonal antibody; network meta-analysis.

Publication types

Comment

MeSH terms

Adult
Antibodies, Monoclonal* / adverse effects
Antibodies, Monoclonal* / therapeutic use
Bayes Theorem*
Humans
Myasthenia Gravis* / drug therapy
Myasthenia Gravis* / immunology
Treatment Outcome

Substances

Antibodies, Monoclonal

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The authors disclosed financial support for the authorship and/or publication of this article. Publication fees were provided by Alexion Pharmaceuticals, AstraZeneca Rare Disease.